Allergy:普通人群中非过敏性鼻炎的患病情况

2022-01-22 MedSci原创 MedSci原创

AR和NAR具有明显的季节性表现,其中NAR在秋季/冬季更为常见,而AR在春季/夏季更为常见。研究人员关于鼻炎表型患病率的数据可能有助于临床医生预测他们诊所的患者类型,并帮助指导量身定制的治疗方法。

非过敏性鼻炎(NAR)可细分为几种表型:老年人鼻炎、药物性鼻炎、吸烟者鼻炎、职业性鼻炎、激素性鼻炎、味觉性鼻炎和特发性鼻炎。NAR有两种病理生理学内在机理:炎症和神经源性机制。表型可以作为潜在内在机理的指标,因此有助于指导治疗。目前尚不清楚普通人群中每种表型的患病率。

近日,过敏性疾病领域权威杂志Allergy上发表了一篇研究文章,研究人员在荷兰一般人群中进行了基于问卷调查的横断面研究。

一般人群中慢性鼻炎的患病率为40%(N=558,其中65%患有NAR,28%患有AR,7%患者过敏状态未知)。NAR患者(N=363)在10月至2月的主诉明显增多。

患有AR的人(N=159)在4月至8月的主诉明显更多。最常见的NAR表型是特发性鼻炎(39%)和药物性鼻炎(14%),其次是职业性鼻炎(8%)、吸烟者鼻炎(6%)、激素性鼻炎(4%)、味觉性鼻炎(4%)和老年人鼻漏(4%)。最不常见的表型是药物诱导性鼻炎(1%)。NAR组19%的患者不能归类为任何表型。

这是第一项描述一般人群中NAR表型患病率的研究。AR和NAR具有明显的季节性表现,其中NAR在秋季/冬季更为常见,而AR在春季/夏季更为常见。研究人员关于鼻炎表型患病率的数据可能有助于临床医生预测他们诊所的患者类型,并帮助指导量身定制的治疗方法。药物性鼻炎的高患病率令人担忧,因为这是一种潜在可预防的表型。

原始出处:

Klementina S Avdeeva,et al.The prevalence of non-allergic rhinitis phenotypes in the general population: a cross-sectional study.Allergy.2022.https://onlinelibrary.wiley.com/doi/10.1111/all.15223?af=R

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1765171, encodeId=77fc1e65171fb, content=<a href='/topic/show?id=df00e086653' target=_blank style='color:#2F92EE;'>#病情#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70866, encryptionId=df00e086653, topicName=病情)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Thu Sep 08 01:03:29 CST 2022, time=2022-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047460, encodeId=0c76204e46098, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sun Apr 03 02:03:29 CST 2022, time=2022-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955721, encodeId=f1e41955e215e, content=<a href='/topic/show?id=4f6599e04e9' target=_blank style='color:#2F92EE;'>#非过敏性鼻炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99704, encryptionId=4f6599e04e9, topicName=非过敏性鼻炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c31495, createdName=liuyg0228, createdTime=Thu Nov 24 14:03:29 CST 2022, time=2022-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329594, encodeId=b6eb13295948c, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Mon Jan 24 12:03:29 CST 2022, time=2022-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614794, encodeId=25d81614e943a, content=<a href='/topic/show?id=b77f59959f2' target=_blank style='color:#2F92EE;'>#普通人群#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59959, encryptionId=b77f59959f2, topicName=普通人群)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1b9519540847, createdName=ms9476844295372110, createdTime=Mon Jan 24 12:03:29 CST 2022, time=2022-01-24, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1765171, encodeId=77fc1e65171fb, content=<a href='/topic/show?id=df00e086653' target=_blank style='color:#2F92EE;'>#病情#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70866, encryptionId=df00e086653, topicName=病情)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Thu Sep 08 01:03:29 CST 2022, time=2022-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047460, encodeId=0c76204e46098, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sun Apr 03 02:03:29 CST 2022, time=2022-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955721, encodeId=f1e41955e215e, content=<a href='/topic/show?id=4f6599e04e9' target=_blank style='color:#2F92EE;'>#非过敏性鼻炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99704, encryptionId=4f6599e04e9, topicName=非过敏性鼻炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c31495, createdName=liuyg0228, createdTime=Thu Nov 24 14:03:29 CST 2022, time=2022-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329594, encodeId=b6eb13295948c, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Mon Jan 24 12:03:29 CST 2022, time=2022-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614794, encodeId=25d81614e943a, content=<a href='/topic/show?id=b77f59959f2' target=_blank style='color:#2F92EE;'>#普通人群#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59959, encryptionId=b77f59959f2, topicName=普通人群)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1b9519540847, createdName=ms9476844295372110, createdTime=Mon Jan 24 12:03:29 CST 2022, time=2022-01-24, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1765171, encodeId=77fc1e65171fb, content=<a href='/topic/show?id=df00e086653' target=_blank style='color:#2F92EE;'>#病情#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70866, encryptionId=df00e086653, topicName=病情)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Thu Sep 08 01:03:29 CST 2022, time=2022-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047460, encodeId=0c76204e46098, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sun Apr 03 02:03:29 CST 2022, time=2022-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955721, encodeId=f1e41955e215e, content=<a href='/topic/show?id=4f6599e04e9' target=_blank style='color:#2F92EE;'>#非过敏性鼻炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99704, encryptionId=4f6599e04e9, topicName=非过敏性鼻炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c31495, createdName=liuyg0228, createdTime=Thu Nov 24 14:03:29 CST 2022, time=2022-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329594, encodeId=b6eb13295948c, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Mon Jan 24 12:03:29 CST 2022, time=2022-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614794, encodeId=25d81614e943a, content=<a href='/topic/show?id=b77f59959f2' target=_blank style='color:#2F92EE;'>#普通人群#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59959, encryptionId=b77f59959f2, topicName=普通人群)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1b9519540847, createdName=ms9476844295372110, createdTime=Mon Jan 24 12:03:29 CST 2022, time=2022-01-24, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1765171, encodeId=77fc1e65171fb, content=<a href='/topic/show?id=df00e086653' target=_blank style='color:#2F92EE;'>#病情#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70866, encryptionId=df00e086653, topicName=病情)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Thu Sep 08 01:03:29 CST 2022, time=2022-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047460, encodeId=0c76204e46098, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sun Apr 03 02:03:29 CST 2022, time=2022-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955721, encodeId=f1e41955e215e, content=<a href='/topic/show?id=4f6599e04e9' target=_blank style='color:#2F92EE;'>#非过敏性鼻炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99704, encryptionId=4f6599e04e9, topicName=非过敏性鼻炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c31495, createdName=liuyg0228, createdTime=Thu Nov 24 14:03:29 CST 2022, time=2022-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329594, encodeId=b6eb13295948c, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Mon Jan 24 12:03:29 CST 2022, time=2022-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614794, encodeId=25d81614e943a, content=<a href='/topic/show?id=b77f59959f2' target=_blank style='color:#2F92EE;'>#普通人群#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59959, encryptionId=b77f59959f2, topicName=普通人群)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1b9519540847, createdName=ms9476844295372110, createdTime=Mon Jan 24 12:03:29 CST 2022, time=2022-01-24, status=1, ipAttribution=)]
    2022-01-24 智智灵药
  5. [GetPortalCommentsPageByObjectIdResponse(id=1765171, encodeId=77fc1e65171fb, content=<a href='/topic/show?id=df00e086653' target=_blank style='color:#2F92EE;'>#病情#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70866, encryptionId=df00e086653, topicName=病情)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Thu Sep 08 01:03:29 CST 2022, time=2022-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047460, encodeId=0c76204e46098, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sun Apr 03 02:03:29 CST 2022, time=2022-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955721, encodeId=f1e41955e215e, content=<a href='/topic/show?id=4f6599e04e9' target=_blank style='color:#2F92EE;'>#非过敏性鼻炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99704, encryptionId=4f6599e04e9, topicName=非过敏性鼻炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c31495, createdName=liuyg0228, createdTime=Thu Nov 24 14:03:29 CST 2022, time=2022-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329594, encodeId=b6eb13295948c, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Mon Jan 24 12:03:29 CST 2022, time=2022-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614794, encodeId=25d81614e943a, content=<a href='/topic/show?id=b77f59959f2' target=_blank style='color:#2F92EE;'>#普通人群#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59959, encryptionId=b77f59959f2, topicName=普通人群)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1b9519540847, createdName=ms9476844295372110, createdTime=Mon Jan 24 12:03:29 CST 2022, time=2022-01-24, status=1, ipAttribution=)]

相关资讯

心理所发现抑郁症状在普通人群中也存在性别差异

人均国内生产总值和男性抑郁均值(红色)、女性抑郁均值(蓝色)以及抑郁性别差异(黑色)的散点图。抑郁症存在比较明显的性别差异,临床观察表明就诊的女性的数量是男性的两倍。这个数据也获得大规模流行病学调查和社区调查的支持。导致这种性别差异的原因尚不清楚,目前比较流行的观点主要有两种。社会性别角色理论(social gender role theory)强调,长久以来女性在许多文化中处于不利地位,更可能体

JAMA:普通人群无症状颈动脉狭窄筛查是否有必要仍无定论

颈动脉狭窄是已知的中风危险因素和心血管疾病标志物。尚未进行以人群为基础的颈动脉狭窄筛查试验。对于临床显著的无症状颈动脉狭窄的最佳治疗方法仍不确定。

国际宇航科学院院士:让航天医学为普通人群健康服务

国际宇航科学院院士、航天中心医院院长杜继臣在京表示,应综合利用航天员健康保障方式方法及技术,解决普通人群相关健康问题。在“第三届北京大学国际脑研究高峰论坛—航天医学与医工结合论坛”上,杜继臣对于航天医学未来发展前景提出了建议。除了前述建议,还包括建立航天医学一级学科,培养特因环境下新型医疗人才;建立新型航天医疗体系,实现集航天特因环境下健康评估、健康防护、健康救助、健康恢复、医学研发等方面的综合医

cerebral cortex: 罪犯和普通人群精神病的神经基础

精神病的特征是持续的反社会行为、共情受损和利己主义。这些特征在正常功能的个体中也有所不同。尽管精神病患者与健康对照者之间巨大的心理差异使得精神疾病的法医影像学研究变得复杂,但临床混杂因素和药物使用史使

Liver Int:瞬时弹性成像对非酒精性脂肪性肝病患病率和严重性的评估

研究表明,在一般人群中,NAFLD的患病率非常高。在NAFLD患者中,有相当比例的患者有晚期纤维化(较高的LSM值)。除了传统的风险因素外,遗传因素也可能具有重要的作用,需要进一步研究。

Eur Heart J:普通人群中 高血脂水平变异性是否与健康相关不良结局相关?

发表在《Eur Heart J》上的一项基于全国人群的研究,考察了在普通人群中,高血脂水平变异性是否与健康相关不良结局存在相关性。